Join the club for FREE to access the whole archive and other member benefits.

Apollo Health Ventures

Venture capital firm investing in seed and early stage biotechnology companies

Apollo Health Ventures is an Early Stage Investment Firm interested in accelerating breakthrough scientific discoveries to the clinic by building life science companies around new therapeutic technologies. Apollo Ventures focuses on assets with the potential to treat, prevent, or even reverse age-related diseases such as Alzheimer's, Heart Disease, Sarcopenia, Frailty, and Cancer, with the ultimate goal of increasing healthy human lifespan. Apollo invests in early stage companies, works with scientists and entrepreneurs to create new ventures, and engages in hypothesis-driven company building.

Visit website:



People at Apollo Health Ventures

Jan Adams

Partner at Apollo Health Ventures

Alexandra Bause

Co-Founder, Investment Director & Head of VentureLabs, Co-Founder at Apollo Health Ventures

Ole Mensching

Co-Founder of Apollo Ventures

Marianne Mertens

Partner at Apollo Health Ventures

Nils Regge

Co-Founder and Managing Director at Apollo Ventures

Apollo Health Ventures News

Focal Biosciences launched by PSI and Apollo Health Ventures

Business Wire - 11-Oct-2022

Aims to treat age-related diseases using advanced cellular reprogramming technologies


$2.5M seed financing round closed by Cleara Biotech-targets cellular senescence

Longevity Technology - 03-Oct-2022

Cleara’s novel FOXO4-based treatment approach-ability to eliminate biomarker-positive scarred cells


$100M fund - Life Extension Ventures might back startups working on longevity

TechCrunch - 18-Sep-2022

Founders are excited to find the impact when software intersects science


Apollo Health Ventures raised $180M fund to invest in longevity innovations

Endpoints News - 01-Dec-2021

Invests in early stage companies that target root causes of age-related diseases


LEAF interviews Dr. Ole Mensching about Apollo Health Ventures' Moonshot Venture (LEAF) - 06-May-2020

VCs are starting to recognise ageing as a problem with a massive business opportunity


Samsara secures more funding for cellular rejuvenation drug research (LEAF) - 06-Mar-2019

Drugs will need to work better than the free alternative - calorie restriction


Cleara Biotech Joins the Race to Develop Senolytic Therapies (LEAF) - 09-Jul-2018

This therapy uses a modified FOXO4 to promote apoptosis in senescent cells